Plural Nitrogens Patents (Class 562/448)
  • Patent number: 8987508
    Abstract: The present invention generally relies on a process for the preparation of chelated compounds, comprising the selective interaction between a solid matrix and a chelating agent. In more details, the present invention enables the preparation of chelated compounds useful as diagnostic agents, in high yields and in a reliable way.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: March 24, 2015
    Assignee: Bracco Imaging S.p.A.
    Inventors: Federico Maisano, Federico Crivellin
  • Publication number: 20150072363
    Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose an in vitro method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using phenylacetylglutamine (PAG) as biomarker.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 12, 2015
    Inventors: Sebastiano Collino, Ivan Montoliu Roura, Francois-Pierre Martin, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
  • Publication number: 20140323719
    Abstract: The present invention relates to an improved process for the purification of polyaminocarboxylates such as DOTA, DTPA, DO3A-butrol, BOPTA.
    Type: Application
    Filed: November 26, 2012
    Publication date: October 30, 2014
    Inventors: Jagadeesh Babu Rangisetty, Manik Reddy Pullaguria, Rajesh Bhudeti
  • Publication number: 20140303395
    Abstract: The present invention relates to the use of oligohydroxybenzoic acid derivatives in washing and cleaning agents in order to improve washing or cleaning performance with respect to bleachable stains.
    Type: Application
    Filed: June 18, 2014
    Publication date: October 9, 2014
    Inventors: Christian Kropf, Mareile Job, Christian Umbreit, Siglinde Erpenbach
  • Publication number: 20140163042
    Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(?O), —S(?O)2—, —C(?O)O—, —C(O)NR3—, —C(?S)—NR3, —C(?NH)NR3 or —S(?O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X2-Q1- or -Q1-X2— wherein X2 is —O—, S— or NRA— wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic r
    Type: Application
    Filed: February 13, 2014
    Publication date: June 12, 2014
    Applicant: Chroma Therapeutics Ltd.
    Inventors: Alan Hornsby Davidson, Sanjay Ratilal Patel, Francesca Ann Mazzei, Stephen John Davies, Alan Hastings Drummond, David Festus Charles Moffat, Kenneth William John Baker, Alastair David Graham Donald
  • Patent number: 8722927
    Abstract: The present invention is directed to Mannich condensation product sequestering agents or mixtures of Mannich condensation product sequestering agents for use in fuels and lubricating oils. The present invention is also directed to a process for preparing the Mannich condensation product sequestering agents. The present invention is also directed to a product formed by combining, under reaction conditions, a polyisobutyl-substituted hydroxyaromatic compound, an aldehyde, an amino acid or ester thereof, and an alkali metal base to form the Mannich condensation product sequestering agent. The present invention is also directed to a lubricating oil composition, a lubricating oil concentrate, a fuel composition, and a fuel concentrate having the Mannich condensation product sequestering agents of the present invention.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: May 13, 2014
    Assignee: Chevron Oronite Company LLC
    Inventors: James J. Harrison, Kenneth D. Nelson
  • Patent number: 8716521
    Abstract: This invention provides stable, lyophilized formulations of canfosfamide as well as the methods of preparation of those stable lyophilized formulations.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: May 6, 2014
    Assignee: Telik, Inc.
    Inventors: Betsy R. Hughes, Robert Steven Lopez
  • Publication number: 20140100357
    Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one aromatic amine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one alkylated amine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Application
    Filed: August 23, 2013
    Publication date: April 10, 2014
    Applicant: Ambrx, Inc.
    Inventors: Zhenwei Miao, Junjie Liu, Thea Norman
  • Publication number: 20140018303
    Abstract: The present invention relates to a novel compound, 3-amino-2-hydroxy-4-phenylbutanoyl-valyl-isoleucine with structure showed below. The compound is prepared from fermentation culture Streptomyces parvus CGMCC No. 4027 and is active as inhibitor of aminopeptidase. It can be used for preparation of aminopeptidase inhibitor.
    Type: Application
    Filed: November 16, 2011
    Publication date: January 16, 2014
    Applicant: SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D
    Inventors: Min Rao, Mei Ge, Minyu Luo, Lijun Ruan, Xing Xia, Li Zhu, Lingao Ruan, Huaixia Kang, Tian Yang, Tianjiao Wang, Qiushuang Li, Hanyan Jiang
  • Patent number: 8623661
    Abstract: The present invention provides an iron chelating agent which can selectively chelate iron ions. The iron chelating agent of the present invention includes a compound represented by the following formula (1) or a salt thereof (wherein, ring Z represents an aromatic hydrocarbon ring or an aromatic heterocyclic ring; R1 represents an alkylene group; R2 and R3 each independently represent a hydrogen atom, a hydrocarbon group or a group having chelating ability; and the total coordination number of the groups represented by R2 and R3 is 1 or 2.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: January 7, 2014
    Assignees: National University Corporation Asahikawa Medical College, Yamagata University
    Inventors: Yutaka Kohgo, Katsuya Ikuta, Katsunori Sasaki, Yuzo Nishida
  • Publication number: 20130345466
    Abstract: The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 26, 2013
    Applicant: THERAVANCE, INC.
    Inventors: Sean M. Dalziel, Miroslav Rapta
  • Publication number: 20130281394
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
    Type: Application
    Filed: October 18, 2011
    Publication date: October 24, 2013
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
  • Patent number: 8524194
    Abstract: The invention is directed to radiolabelled MMP selective compounds, a processes for the preparation thereof, and uses thereof. The derivatives of the invention have formula (I) wherein Y represents O, CH2, (CH2)2, S, NH, or C(?O)NH; X represents 1-5 substituents, wherein said substituents can be the same or different and wherein at least one of said substituents comprises a radioisotope suitable for PET and/or SPECT and/or a ?-emitter; Z is S; Q is chosen from the group consisting of 3-pyridyl and carboxyl; and R is chosen from the group consisting of C(?O)—NH—OH, (II), (III, (IV). The MMP selective compounds of the invention are selective for MMPs and can be used for the identification and treatment of unstable atherosclerotic plaques.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 3, 2013
    Assignee: Academisch Medisch Centrum Bij de Universiteit van Amsterdam
    Inventors: Bertha Louise Frederike Van Eck-Smit, Victorine Augustine Pinas, Albert Dirk Windhorst
  • Patent number: 8481781
    Abstract: Formulations of canfosfamide and their preparation.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: July 9, 2013
    Assignee: Telik, Inc.
    Inventors: Betsy R. Hughes, Robert Steven Lopez
  • Publication number: 20130158241
    Abstract: The invention relates to a method for producing crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid of the formula I by saponifying 3,6,9-triaza-3,6,9-tris(tert-butoxycarbonylmethyl)-4-(4-ethoxybenzyl)-undecanedioic acid di-tert-butyl ester of the formula II in an aqueous alkali metal hydroxide solution and using 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid of the formula I for producing the gadolinium complex of 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid [(Gd-EOB-DTPA)=Primovist®].
    Type: Application
    Filed: June 6, 2011
    Publication date: June 20, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Patent number: 8455681
    Abstract: The present invention is directed to Mannich condensation product sequestering agents or mixtures of Mannich condensation product sequestering agents for use in fuels and lubricating oils. The present invention is also directed to a process for preparing the Mannich condensation product sequestering agents. The present invention is also directed to a product formed by combining, under reaction conditions, a polyisobutyl-substituted hydroxyaromatic compound, an aldehyde, an amino acid or ester thereof, and an alkali metal base to form the Mannich condensation product sequestering agent. The present invention is also directed to a lubricating oil composition, a lubricating oil concentrate, a fuel composition, and a fuel concentrate having the Mannich condensation product sequestering agents of the present invention.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: June 4, 2013
    Assignee: Chevron Oronite Company LLC
    Inventors: James J. Harrison, Kenneth D. Nelson
  • Publication number: 20130137635
    Abstract: This invention relates to tryptophan hydroxylase inhibitors, compositions comprising them, and methods of their use for the treatment, management and/or prevention of metastatic bone disease.
    Type: Application
    Filed: February 9, 2011
    Publication date: May 30, 2013
    Applicant: LEXICON PHARMACEUTICALS, INC.
    Inventor: Arthur Thomas Sands
  • Patent number: 8431734
    Abstract: The invention relates to a process for the preparation of N,N?-bis(2-hydroxybenzyl)-ethylenediamine-N,N?-diacetic acid and its derivatives of general formula (I), wherein both R have the same meaning and are selected from H, C1-C4alkyl, CH2OH, SO3M, and COOM; and all M have the same meaning and represent hydrogen atom, Na, K or NH4; which comprises reductive amination of glyoxylic acid with a salan compound of general formula (II), in the presence of an amine proton acceptor. The compounds of formula (I) can be used as chelating agents for micronutrients in fertilizer preparations for plants.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: April 30, 2013
    Assignee: Przedsiebiorstwo Produkeyjno-Consultingowe Adob SP. Z O.O. SP. K.
    Inventors: Adam Nawrocki, Filip Stefaniak, Anika Mrozek-Niecko, Radoslaw Olszewski
  • Publication number: 20130102570
    Abstract: A medicament having an excellent CaSR agonist action which enables the prevention or treatment of diabetes or obesity is provided by a composition comprising the compound represented by general formula (I) as defined, or a salt thereof.
    Type: Application
    Filed: September 28, 2012
    Publication date: April 25, 2013
    Applicant: AJINOMOTO CO., INC.
    Inventor: AJINOMOTO CO., INC
  • Publication number: 20130096127
    Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: November 29, 2012
    Publication date: April 18, 2013
    Applicant: NOVARTIS AG
    Inventor: NOVARTIS AG
  • Publication number: 20130079383
    Abstract: The invention relates to the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein n, G, W, X, Y, and R1 are defined in the detailed description and claims. The compounds of formula I bind to or associate with VLA-4 and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing VLA-4.
    Type: Application
    Filed: July 5, 2012
    Publication date: March 28, 2013
    Applicant: ARROWHEAD RESEARCH CORPORATION
    Inventors: John Frederick BOYLAN, Robert A. GOODNOW, Wei HE, Tai-An LIN, Achyutharao SIDDURI
  • Publication number: 20130005918
    Abstract: Polymeric polyamine is produced by polymerizing polyoxyalkylene-amine and a linker. The polyoxyalkylene-amine has a structural formula H2N—R—NH2, wherein R is selected from the group consisting of dianhydride, diacid, epoxy, diisocyanate and poly(styrene-co-maleic anhydride) copolymers (SMA). The linker can be anhydride, carboxylic acid, epoxy, isocyanate or poly(styrene-co-maleic anhydride) copolymers (SMA). The polymeric polyamine so produced can be used as a stabilizer or dispersant of the Ag nanoparticles.
    Type: Application
    Filed: September 12, 2012
    Publication date: January 3, 2013
    Applicant: NATIONAL TAIWAN UNIVERSITY
    Inventors: Jiang-Jen Lin, Wei-Cheng Tsai, Yen-Chi Hsu, Wen-Hsin Chang
  • Publication number: 20120329716
    Abstract: The instant invention relates to peptides obtained from the enzymatic hydrolysis of yellow pea seed proteins that are capable of lowering the blood pressure and reducing the effects of kidney disease in a subject b\ inhibiting or reducing the affinity of the enzymes in the renin-angiotensin system for their substrates, specifically renin, to compositions comprising said peptides and to uses thereof.
    Type: Application
    Filed: October 28, 2010
    Publication date: December 27, 2012
    Inventors: Rotimi Aluko, Jianping Wu, Harold Aukema
  • Publication number: 20120316171
    Abstract: Methods and compositions for the treatment and/or management of cancer are disclosed, which comprise the use of tryptophan hydroxylase inhibitors.
    Type: Application
    Filed: November 4, 2010
    Publication date: December 13, 2012
    Inventor: Tamas Oravecz
  • Publication number: 20120309944
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.
    Type: Application
    Filed: January 24, 2011
    Publication date: December 6, 2012
    Applicant: Novo Nordisk Health Care AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Patent number: 8324426
    Abstract: This invention provides stable, lyophilized formulations of canfosfamide as well as the methods of preparation of those stable lyophilized formulations.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: December 4, 2012
    Assignee: Telik, Inc.
    Inventors: Betsy R. Hughes, Robert Steven Lopez
  • Publication number: 20120302641
    Abstract: The present invention is directed to biphenyl derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: May 23, 2012
    Publication date: November 29, 2012
    Inventors: Devraj Chakravarty, Michael Greco, Brian Shook, Guozhang Xu, Rui Zhang
  • Publication number: 20120289554
    Abstract: This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula wherein A1, A2, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments in methods for the treatment of diseases modulated by CPT2 inhibitors.
    Type: Application
    Filed: July 24, 2012
    Publication date: November 15, 2012
    Inventors: Mirjana Andjelkovic, Simona M. Ceccarelli, Odile Chomienne, Gerald Lewis Kaplan, Patrizio Mattei, Jefferson Wright Tilley
  • Publication number: 20120277310
    Abstract: A conjugate comprising L-DOPA covalently linked to at least one ?-aminobutyric acid (GABA) moiety, an ester and/or an addition salt thereof are disclosed, as well as uses thereof for treating a neurodegenerative disease or disorder.
    Type: Application
    Filed: June 25, 2012
    Publication date: November 1, 2012
    Applicants: Bar-Ilan University, Ramot at Tel-Aviv University Ltd.
    Inventors: Gideon STEIN, Abraham NUDELMAN, Ada REPHAELI, Irit GIL-AD, Abraham WEIZMAN
  • Publication number: 20120270813
    Abstract: A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof.
    Type: Application
    Filed: October 5, 2011
    Publication date: October 25, 2012
    Applicant: Food Industry Research and Development Institute
    Inventors: Yi-Hong Chen, Yu-Hui Liu, Chu-Chin Chen, Shiao-Cheng Chuang, Hsiang-Ling Lai, Chien-Ti Chang, Ming-Yu Hung, Su-Er Liou, Fu-Ning Chien
  • Publication number: 20120253065
    Abstract: The present invention is directed to Mannich condensation product sequestering agents or mixtures of Mannich condensation product sequestering agents for use in fuels and lubricating oils. The present invention is also directed to a process for preparing the Mannich condensation product sequestering agents. The present invention is also directed to a product formed by combining, under reaction conditions, a polyisobutyl-substituted hydroxyaromatic compound, an aldehyde, an amino acid or ester thereof, and an alkali metal base to form the Mannich condensation product sequestering agent. The present invention is also directed to a lubricating oil composition, a lubricating oil concentrate, a fuel composition, and a fuel concentrate having the Mannich condensation product sequestering agents of the present invention.
    Type: Application
    Filed: May 9, 2012
    Publication date: October 4, 2012
    Applicant: Chevron Oronite Company LLC
    Inventors: James J. Harrison, Kenneth D. Nelson
  • Publication number: 20120232151
    Abstract: The present invention discloses a process for the preparation of gadobenate dimeglumine complex in a solid form. In particular, said solid form is conveniently obtained by spray-drying a corresponding liquid suspension at a given temperature and concentration. The present invention is particularly advantageous for the industrial scale as the solid form may be obtained by employing water as a solvent, which is a non-toxic solvent, easy to handle and basically not requiring troublesome health or safety precautions.
    Type: Application
    Filed: November 23, 2010
    Publication date: September 13, 2012
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Pier Lucio Anelli, Pierfrancesco Morisini, Silvia Ceragioli, Fulvio Uggeri, Luciano Lattuada, Roberta Fretta, Aurelia Ferrigato
  • Publication number: 20120196933
    Abstract: The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided.
    Type: Application
    Filed: December 22, 2011
    Publication date: August 2, 2012
    Inventors: Richard Franklin, Bernard T. Golding, Robert G. Tyson
  • Publication number: 20120107835
    Abstract: A method for detecting ?-amyloid using an amino acid dimer instead of a secondary antibody binding to the ?-amyloid primary antibody in an immunoassay based on an antigen-antibody reaction, and a kit for detecting ?-amyloid including the dimer. The method is advantageous in that the dimer has good properties in stability, availability, and storage compared to antibodies and that it can detect various ?-amyloids by using one kind of antibody, and thus may be effectively used in early diagnosis and research of Alzheimer's disease.
    Type: Application
    Filed: October 7, 2011
    Publication date: May 3, 2012
    Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventor: Hyo Bong Hong
  • Publication number: 20120046292
    Abstract: [Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.
    Type: Application
    Filed: April 19, 2010
    Publication date: February 23, 2012
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Tomoaki Kawano, Yasuhiro Yonetoku, Takeshi Hanazawa, Takahiro Nigawara, Hiroki Fukudome, Hiroshi Moritani
  • Publication number: 20120010112
    Abstract: The present invention relates to novel acid-free quaternized nitrogen compounds, to the preparation thereof and to the use thereof as a fuel and lubricant additive, more particularly as a detergent additive, as a wax antisettling additive (WASA) or as an additive for reducing internal diesel injector deposits (IDID); to additive packages which comprise these compounds; and to fuels and lubricants thus additized. The present invention further relates to the use of these acid-free quaternized nitrogen compounds as a fuel additive for reducing or preventing deposits in the injection systems of direct-injection diesel engines, especially in common-rail injection systems, for reducing the fuel consumption of direct-injection diesel engines, especially of diesel engines with common-rail injection systems, and for minimizing power loss in direct-injection diesel engines, especially in diesel engines with common-rail injection systems.
    Type: Application
    Filed: July 6, 2011
    Publication date: January 12, 2012
    Applicant: BASF SE
    Inventors: Wolfgang Grabarse, Harald Böhnke, Christian Tock, Cornelia Röger-Göpfert, Ludwig Völkel
  • Patent number: 8093420
    Abstract: The present invention relates to compounds of formula I and II, which are functionalized amino acids, and polymers formed from the same. Polymers formed from the functionalized amino acids are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: January 10, 2012
    Assignee: Bezwada Biomedical, LLC
    Inventor: Rao S. Bezwada
  • Publication number: 20110263626
    Abstract: The present invention relates to compounds of general formula I wherein n, R1, R2, R3, R4, R5, R6, R7 and R8 are defined as stated hereinafter, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the pharmaceutical compositions containing the pharmacologically effective compounds, the preparation thereof and the use thereof.
    Type: Application
    Filed: August 28, 2008
    Publication date: October 27, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Norbert Hauel, Angelo Ceci, Enzo Cereda, Henri Doods, Ingo Konetzki, Juergen Mack, Henning Priepke, Annette Schuler-metz, Rainer Walter
  • Publication number: 20110262374
    Abstract: The present invention relates to a novel compound having excellent antioxidant activity, isolated from Ramalina terebrata, and more particularly to a novel compound, Ramalin, having excellent antioxidant activity, isolated from the Antarctic lichen Ramalina terebrata, a method for preparing the Ramalin, and a pharmaceutical composition, a functional food and a functional cosmetic composition, which contain the Ramalin as an active ingredient. The Ramalin according to the invention has significantly excellent antioxidant effects compared to commercially available antioxidants, and thus can be widely used in agents for treating oxidation-related diseases, anti-aging functional foods, functional cosmetic products for skin whitening and wrinkle reduction, etc.
    Type: Application
    Filed: November 10, 2009
    Publication date: October 27, 2011
    Inventors: Joung Han Yim, Hong Kum Lee, Hari Datta Bhattarai, Paudel Babita, Il Chan Kim, Soon Gyu Hong, Doc Kyu Kim, Yoo Kyung Lee, Sung Gu Lee, Hyun Cheol Oh
  • Publication number: 20110189779
    Abstract: The present invention provides an iron chelating agent which can selectively chelate iron ions. The iron chelating agent of the present invention includes a compound represented by the following formula (1) or a salt thereof (wherein, ring Z represents an aromatic hydrocarbon ring or an aromatic heterocyclic ring; R1 represents an alkylene group; R2 and R3 each independently represent a hydrogen atom, a hydrocarbon group or a group having chelating ability; and the total coordination number of the groups represented by R2 and R3 is 1 or 2.
    Type: Application
    Filed: September 18, 2009
    Publication date: August 4, 2011
    Applicants: YAMAGATA UNIVERSITY, National University Corporation ASAHIKAWA MEDICAL COLLEGE
    Inventors: Yutaka Kohg, Katsuya Ikuta, Katsunori Sasaki, Yuzo Nishida
  • Publication number: 20110152220
    Abstract: The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
    Type: Application
    Filed: March 30, 2009
    Publication date: June 23, 2011
    Inventors: Gerard Karsenty, Patricia F. Ducy, Yuli Xie, Donald Landry, Vijay Kumar Yadav
  • Publication number: 20110136877
    Abstract: The present invention provides novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin.
    Type: Application
    Filed: January 6, 2009
    Publication date: June 9, 2011
    Applicant: LIGAND PHARMACEUTICALS INC.
    Inventors: Brian F. McGuinness, Thuy X. H. Le, Jingqi Duo, Koc-Kan Ho
  • Patent number: 7935843
    Abstract: The present invention relates to dephenolic compounds, an example of which is shown below, which are functionalized, and polymers formed from the same. Polymers formed from the functionalized diphenolics are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: May 3, 2011
    Assignee: Bezwada Biomedical, LLC
    Inventor: Rao S Bezwada
  • Publication number: 20110076237
    Abstract: In one aspect, the present invention provides a contrast enhancement agent comprising an iron chelate having structure I wherein R1 is independently at each occurrence a hydroxy group, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, and b is 0-4; R2-R7 are independently at each occurrence hydrogen, a C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group, with the proviso that at least one of R1-R7 is a hydroxy group or a C1-C3 hydroxyalkyl group; and wherein Q is a charge balancing counterion. Also provided is a metal chelating ligand having structure IX and medical formulations comprising the contrast enhancement I.
    Type: Application
    Filed: September 30, 2009
    Publication date: March 31, 2011
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: Brian James Grimmond, Michael Todd Luttrell, Jeannette Christine DePuy, Mary Elizabeth Spilker, Michael James Rishel
  • Publication number: 20110039933
    Abstract: The invention provides compounds formula (I), their preparation, and their use as pharmaceutically active immuno-suppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.
    Type: Application
    Filed: August 7, 2007
    Publication date: February 17, 2011
    Applicant: PRAECIS PHARMACEUTICALS INCORPORATION
    Inventors: Ghotas Evindar, Hongfeng Deng
  • Publication number: 20110028552
    Abstract: The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) with amino acids or peptides and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, treating arrhythmia, decreasing the adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided. Oligopeptides incorporating lysine or arginine residues attached directly or indirectly through a glycine residue are also described herein.
    Type: Application
    Filed: June 24, 2010
    Publication date: February 3, 2011
    Inventors: Richard Franklin, Bernard T. Golding, Robert G. Tyson
  • Publication number: 20100178324
    Abstract: The present invention includes methods of making and methods of using peptidomimetics compositions that mimic ?-helical BH3 sequences in cells. The peptidomimetics can be used to mimic ?-helical BH3 sequences and kill cancer cells.
    Type: Application
    Filed: January 13, 2009
    Publication date: July 15, 2010
    Applicant: Board of Regents, The University System
    Inventor: Jung-Mo Ahn
  • Publication number: 20100168079
    Abstract: The present invention relates to biaryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: December 21, 2009
    Publication date: July 1, 2010
    Inventors: Daniela Angst, Birgit Bollbuck, Philipp Janser, Jean Quancard
  • Publication number: 20100168469
    Abstract: The invention relates to a process for the preparation of N,N?-bis(2-hydroxybenzyl)-ethylenediamine-N,N?-diacetic acid and its derivatives of general formula (I), wherein both R have the same meaning and are selected from H, C1-C4alkyl, CH2OH, SO3M, and COOM; and all M have the same meaning and represent hydrogen atom, Na, K or NH4; which comprises reductive amination of glyoxylic acid with a salan compound of general formula (II), in the presence of an amine proton acceptor. The compounds of formula (I) can be used as chelating agents for micronutrients in fertilizer preparations for plants.
    Type: Application
    Filed: September 15, 2008
    Publication date: July 1, 2010
    Applicant: PRZEDSIEBIORSTWO PRODUKCYJNO-CONSULTINGOWE ADOB SP
    Inventors: Adam Nawrocki, Filip Stefaniak, Anika Mrozek-Niecko, Radoslaw Olszewski
  • Patent number: 7696377
    Abstract: It is the objective to provide a method of stabilizing hydroxylamine at a high temperature and a high concentration or in a case that metal impurities such as Fe got mixed therewith, and a stabilized hydroxylamine solution. A method for stabilizing hydroxylamine related to the present invention is characterized by adding ethylenediamine-N,N?-di(o-hydroxyphenylacetic acid) as a preservation stabilizer.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: April 13, 2010
    Assignee: Showa Denko K.K.
    Inventors: Takanori Aoki, Toshitaka Hiro